CATEGORY

Antibody Vaccines

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Antibody Vaccines.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Category Alerts


CATEGORY ALERTS

Brii Biosciences Exercises Option in Greater China for Vir Biotechnology's VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B.

July 12, 2022
alert level: Medium
CATEGORY ALERTS

Brii Biosciences Announces the Commercialization of Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China.

July 14, 2022
alert level: Medium

Become a Beroe LiVE.Ai™ Subscriber to receive proactive alerts on Antibody Vaccines

Antibody Vaccines Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Antibody Vaccines category is 5.40%

Payment Terms

(in days)

The industry average payment terms in Antibody Vaccines category for the current quarter is 73.4 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Antibody Vaccines Suppliers


    1,792
    Total Suppliers
    73
    Diverse Suppliers
    73
    Normalized Supplier Rating
    Antibody Vaccines Supplier

    Find the right-fit antibody vaccines supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Antibody Vaccines market report transcript


    Antibody Vaccines Global Market Outlook:

    Market Growth: CAGR growth rate: $3.28 Billion in 2018 and expected to reach $4.19 Billion by 2022, growing at a CARG of 6.2 percent

    Reduction in availability of targeted researchers and physician is expected, due to outbreak of COVID, which is impacting the antibody vaccine
    development and analytical testing services
    Due to the COVID breakdown, demand for developing antibody vaccine for novel coronavirus is increasing and hence, pharmaceutical
    companies are collaborating with research institutions to enhance the speed of antibody vaccine development

    Porter's Analysis on Antibody Vaccines

    Supplier Power

    • Supplier power is medium as most of the buyers enter into strategic relationships with the preferred suppliers
    • Most of the buyers have particular set of suppliers to be considered for the development process. This is based upon the various technologies and
      processes available.

    Barriers to New Entrants

    • Set up and scale up of mammalian cell cultures require time.
    • Buyers prefer to go for strategic relationships in this category. Suppliers currently existing in the market have working relationships with various buyers and the entry of a new entrant would be difficult.

    Intensity of Rivalry

    • The rivalry faced by the CMOs is not from the direct competitors, but rather an influx of capacity from the players who were product manufacturers earlier.
    • The differences in the established volume, processes, technologies differentiates the various suppliers in the supply space.
    • The CMO space is growing at a rate greater than the increase in demand.

    Threat of Substitutes

    • Monoclonal antibodies operate by mimicking the natural defense mechanism of the human body, and is really effective the areas of Cancer and auto immune diseases.
    • Unless a new technology/process can find an alternative for the treatment, the threat of substitute is really low.

    Buyer Power

    • The utilization rates of the supplier facilities are expected to drop going foreword as the suppliers and buyers are expanding at a rate higher than the
      increase in supply.

    •  Most of the buyers outsource high volumes to a supplier often leading to the allotment of a dedicated space.